Researchers from Alnylam Pharmaceuticals and collaborators published data from a study that aimed to identify novel therapeutic targets for abdominal obesity by searching for genetic variants associated with lower waist-to-hip ratio.
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have divulged thienyl and cycloalkyl aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatment of cancer and fibrosis.
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.
Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features.
The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S.
Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic.
Ozette Technologies has announced USD 26 million in Series A funding. The company is focused on artificial intelligence (AI)-powered single-cell immune discovery technology.
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have discovered isoindolinone aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatement of cancer and fibrosis.
RSS